Found: 9
Select item for more details and to access through your institution.
Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 10, p. 1576, doi. 10.1177/13524585221079731
- By:
- Publication type:
- Article
Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 10, p. 1562, doi. 10.1177/13524585221078825
- By:
- Publication type:
- Article
Effect of ofatumumab versus placebo in relapsing multiple sclerosis patients from Japan and Russia: Phase 2 APOLITOS study.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 8, p. 1229, doi. 10.1177/13524585211055934
- By:
- Publication type:
- Article
Effect of Ofatumumab on Serum Immunoglobulin Levels and Infection Risk in Relapsing Multiple Sclerosis Patients from the Phase 3 ASCLEPIOS I and II Trials.
- Published in:
- International Journal of MS Care, 2020, v. 22, n. S2, p. 85
- By:
- Publication type:
- Article
(DXT61) Injection-Related Reactions with Subcutaneous Administration of Ofatumumab in Relapsing Multiple Sclerosis: Pooled Analysis of the Phase 3 ASCLEPIOS I and II Trials.
- Published in:
- International Journal of MS Care, 2020, v. 22, n. S2, p. 38
- By:
- Publication type:
- Article
(DMT03) Efficacy and Safety of Ofatumumab Versus Teriflunomide in Patients with Relapsing Multiple Sclerosis: Phase 3 ASCLEPIOS I and II Trials.
- Published in:
- International Journal of MS Care, 2020, v. 22, n. S2, p. 4
- By:
- Publication type:
- Article
Correction to: COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab.
- Published in:
- Neurology & Therapy, 2022, v. 11, n. 2, p. 741, doi. 10.1007/s40120-022-00341-z
- By:
- Publication type:
- Article
Population Pharmacokinetic–B Cell Modeling for Ofatumumab in Patients with Relapsing Multiple Sclerosis.
- Published in:
- CNS Drugs, 2022, v. 36, n. 3, p. 283, doi. 10.1007/s40263-021-00895-w
- By:
- Publication type:
- Article